These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 7836766)

  • 1. Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody.
    Yuan R; Casadevall A; Spira G; Scharff MD
    J Immunol; 1995 Feb; 154(4):1810-6. PubMed ID: 7836766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in mice.
    Yuan RR; Spira G; Oh J; Paizi M; Casadevall A; Scharff MD
    Infect Immun; 1998 Mar; 66(3):1057-62. PubMed ID: 9488395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.
    Mukherjee J; Kozel TR; Casadevall A
    J Immunol; 1998 Oct; 161(7):3557-68. PubMed ID: 9759877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection.
    Feldmesser M; Casadevall A
    J Immunol; 1997 Jan; 158(2):790-9. PubMed ID: 8992996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan.
    Maitta RW; Datta K; Pirofski LA
    Vaccine; 2004 Sep; 22(29-30):4062-8. PubMed ID: 15364457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans.
    Nussbaum G; Yuan R; Casadevall A; Scharff MD
    J Exp Med; 1996 Apr; 183(4):1905-9. PubMed ID: 8666947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective murine monoclonal antibodies to Cryptococcus neoformans.
    Mukherjee J; Scharff MD; Casadevall A
    Infect Immun; 1992 Nov; 60(11):4534-41. PubMed ID: 1398966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.
    Beenhouwer DO; Shapiro S; Feldmesser M; Casadevall A; Scharff MD
    Infect Immun; 2001 Oct; 69(10):6445-55. PubMed ID: 11553589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3.
    Shapiro S; Beenhouwer DO; Feldmesser M; Taborda C; Carroll MC; Casadevall A; Scharff MD
    Infect Immun; 2002 May; 70(5):2598-604. PubMed ID: 11953401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-glucuronoxylomannan IgG1 specific antibodies production in Cryptococcus neoformans resistant mice.
    Parra C; González JM; Castañeda E; Fiorentino S
    Biomedica; 2005 Mar; 25(1):110-9. PubMed ID: 15962907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages.
    Mukherjee S; Lee SC; Casadevall A
    Infect Immun; 1995 Feb; 63(2):573-9. PubMed ID: 7822024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles.
    Maitta RW; Datta K; Chang Q; Luo RX; Witover B; Subramaniam K; Pirofski LA
    Infect Immun; 2004 Aug; 72(8):4810-8. PubMed ID: 15271943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cryptococcus neoformans infection can elicit protective antibodies in mice.
    Mukherjee J; Scharff MD; Casadevall A
    Can J Microbiol; 1994 Oct; 40(10):888-92. PubMed ID: 8000967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibody-mediated toxicity in Cryptococcus neoformans infection: mechanism and relationship to antibody isotype.
    Lendvai N; Casadevall A
    J Infect Dis; 1999 Sep; 180(3):791-801. PubMed ID: 10438368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.
    Beenhouwer DO; Yoo EM; Lai CW; Rocha MA; Morrison SL
    Infect Immun; 2007 Mar; 75(3):1424-35. PubMed ID: 17220317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide.
    Valadon P; Nussbaum G; Oh J; Scharff MD
    J Immunol; 1998 Aug; 161(4):1829-36. PubMed ID: 9712050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide libraries define the fine specificity of anti-polysaccharide antibodies to Cryptococcus neoformans.
    Valadon P; Nussbaum G; Boyd LF; Margulies DH; Scharff MD
    J Mol Biol; 1996 Aug; 261(1):11-22. PubMed ID: 8760499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of biologically active anti-Cryptococcus neoformans IgG, IgE and IgA isotype switch variant antibodies by acridine orange mutagenesis.
    Spira G; Paizi M; Mazar S; Nussbaum G; Mukherjee S; Casadevall A
    Clin Exp Immunol; 1996 Sep; 105(3):436-42. PubMed ID: 8809131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection.
    Casadevall A; Mukherjee J; Devi SJ; Schneerson R; Robbins JB; Scharff MD
    J Infect Dis; 1992 Jun; 165(6):1086-93. PubMed ID: 1583327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis for immunoglobulin M specificity to epitopes in Cryptococcus neoformans polysaccharide that elicit protective and nonprotective antibodies.
    Nakouzi A; Valadon P; Nosanchuk J; Green N; Casadevall A
    Infect Immun; 2001 May; 69(5):3398-409. PubMed ID: 11292763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.